Sandoz to Acquire Interchangeable Lucentis Biosimilar Cimerli
January 22nd 2024The biosimilar Cimerli carries the interchangeability designation for the treatment of wet age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, and diabetic retinopathy.